Current developments in nucleoside/nucleotide analogues for hepatitis B

Expert Review of Gastroenterology and Hepatology

Volumn 8, Issue 6, 2014, Pages 607-622

  Lo, Angeline Oi Shan ^a   Wong, Grace Lai Hung ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

adefovir; cost effectiveness; drug resistance; entecavir; HBV DNA polymerase; lamivudine; roadmap approach; suboptimal responders; telbivudine; tenofovir disoproxil fumarate

Indexed keywords

ADEFOVIR DIPIVOXIL; ADENOSINE PHOSPHATE; BESIFOVIR; CLEVUDINE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; LB80280; NUCLEOSIDE ANALOG; NUCLEOTIDE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PLACEBO; TELBIVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; VIRUS DNA; ANTIVIRUS AGENT; NUCLEOSIDE;

ADD ON THERAPY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; FLU LIKE SYNDROME; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HYPOPHOSPHATEMIA; IMMUNOMODULATION; LIVER BIOPSY; MONOTHERAPY; MOOD DISORDER; NEPHROTOXICITY; NEUTROPENIA; OSTEOMALACIA; PREVALENCE; REVIEW; RISK REDUCTION; THROMBOCYTOPENIA; THYROID DISEASE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS REPLICATION; ANIMAL; ANTIVIRAL RESISTANCE; DRUG COMBINATION; DRUG DESIGN; DRUG EFFECTS; GENETICS; HEPATITIS B, CHRONIC; IMMUNOLOGY; TIME;

ANIMALS; ANTIVIRAL AGENTS; DRUG DESIGN; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; NUCLEOSIDES; NUCLEOTIDES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84904472348     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2014.909724     Document Type: Review

References (143)

1. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: New estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012;30:2212-19
2. Chan HL, Jia JD. Chronic Hepatitis B in Asia-new insights from the past decade. J Gastroenterol Hepatol 2011;26(Suppl 1): 131-7
3. Dan YY, Aung MO, Lim SG. The economics of treating chronic hepatitis B in Asia. Hepatol Int 2008;2:284-95
4. Jonas MM. Hepatitis B and pregnancy: An underestimated issue. Liver Int 2009; 29(Suppl 1):133-9
5. Davis LG, Weber DJ, Lemon SM. Horizontal transmission of hepatitis B virus. Lancet 1989;1(8643):889-93
6. World Health Organization. Immunization, vaccines and biologicals. Available from: Www.who.int/immunization/topics/hepatitis-b/en/index.html
7. Sung JJ, Tsoi KK, Wong VW, et al. Metaanalysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008;28:1067-77
8. Chan HL, Sung JJ. Hepatocellular carcinoma and hepatitis B virus. The Control of Chronic Hepatitis B: The role of chemoprevention. Semin Liver Dis 2006;26: 153-61
9. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73
10. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-86
11. Chan HL, Tse CH, Mo F, et al. High viral load and hepatitis B virus subgenotype Ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol 2008;26:177-82
12. Wong VW, Chan SL, Mo F, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol 2010;28:1660-5
13. Yuen MF, Tanaka Y, Fong DY, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 2009;50:80-8
14. Yang HI, Yuen MF, Chan HL, et al. Development and validation of a predictive score describing risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): Prospective analysis. Lancet Oncol 2011;12:568-74
15. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2009;50:661-2
16. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J Hepatol 2012;57:167-85
17. Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: 1 2012 update. Hepatol Int 2012;6:531-61
18. Castera L, Pinzani M, Bosch J. Non-invasive evaluation of portal hypertension using transient elastography. J Hepatol 2012;56:696-703
19. Wong GL. Transient elastography: Kill two birds with one stone?. World J Hepatol 2013;5:264-74
20. Chan HL, Wong GL, Choi PC, et al. Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. J Viral Hepat 2009;16: 36-44
21. Wong GL, Wong VW, Choi PC, et al. Clinical factors associated with liver stiffness in hepatitis B e antigen-positive chronic hepatitis B patients. Clin Gastroenterol Hepatol 2009;7:227-33
22. Tong MJ, Hsien C, Hsu L, et al. Treatment recommendations for chronic hepatitis B: An evaluation of current guidelines based on a natural history study in the United States. Hepatology 2008;48: 1070-8
23. Wong DK, Cheung AM, O'Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-Analysis. Ann Intern Med 1993;119:312-23
24. Vial T, Descotes J. Clinical toxicity of the interferons. Drug Saf 1994;10:115-50
25. Wong VW, Wong GL, Yan KK, et al. Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen positive chronic hepatitis B. Hepatology 2010;51:1945-53
26. Wong GL, Chan HL. Predictors of treatment response in chronic hepatitis B. Drug 2009;69:2167-77
27. Lai CL, Chien RN, Leung WY, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia hepatitis lamivudine study group. N Engl J Med 1998;339:61-8
28. Seok JI, Lee DK, Lee CH, et al. Long-Term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA. Hepatology 2009;49:2080-6
29. Kim BK, Oh J, Kwon SY, et al. Clevudine myopathy in patients with chronic hepatitis B. J Hepatol 2009;51:829-34
30. Chan HL. Antiviral therapy for chronic hepatitis B: The challenges of Hong Kong. J Hepatol 2009;51:1088-90
31. Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007. 5: 890-7
32. Nassal M. Hepatitis B viruses: Reverse transcription a different way. Virus Res 2008;134:235-49
33. Urban S, Schulze A, Dandri M, et al. The replication cycle of hepatitis B virus. J Hepatol 2010;52:282-4
34. Chan HL, Thompson A, Martinot-Peignoux M, et al. Hepatitis B surface antigen quantification: Why and how to use it in 2011-A core group report. J Hepatol 2011;55:1121-31
35. Chan HL, Wang H, Niu J, et al. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: A double-blind, placebo-controlled trial. Antivir Ther 2007;12:345-53
36. Hadziyannis SJ, Sevastianos V, Rapti IN, et al. Sustained biochemical and virological remission after discontinuation of 4 to 5 years of adefovir dipivoxil (ADV) treatment in HBeAg-negative chronic hepatitis B. Hepatology 2006;44(Suppl1): 231A
37. Jeng WJ, Sheen IS, Chen YC, et al. Off-Therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients. Hepatology 2013;58:1888-96
38. Reijnders JG, Perquin MJ, Zhang N, et al. Nucleos(t)ide analogs only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology 2010;139(2): 491-8
39. Dienstag JL, Cianciara J, Karayalcin S, et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003;37:748-55
40. Poynard T, Hou J, Chutaputti A, et al. Sustained durability of HBeAg seroconversion in chronic hepatitis B patients after treatment with telbivudine and lamivudine. J Hepatol 2008;48:S263
41. Jaroszewicz J, Calle Serrano B, Wursthorn K, et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: A European perspective. J Hepatol 2010;52: 514-22
42. Chan HL, Wong VW, Tse AM, et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 2007;5:1462-8
43. Chan HL, Wong VW, Wong GL, et al. A longitudinal study on the natural history of serum HBsAg changes in chronic hepatitis B. Hepatology 2010;52:1232-41
44. Jaroszewicz J, Ho H, Deterding K, et al. Prediction of HBsAg loss by quantitative HBsAg kinetics during long-Term treatment with nucleos(t)ide analogues. Hepatology 2010;52:Abstract 395
45. Reijnders JG, Rijckborst V, Sonneveld MJ, et al. Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. J Hepatol 2011;54:449-54
46. Seto WK, Liu K, Wong DK, et al. Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment. J Hepatol 2013;59(4):709-16
47. Brunetto MR, Oliveri F, Colombatto P, et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis virus genotype D carriers. Gastroenterology 2010;139:483-90
48. Chan HL, Wong GL, Tse CH, et al. Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients. J Infect Dis 2011;204:408-14
49. Seto WK, Wong DK, Fung J, et al. A large case-control study on the predictability of hepatitis B surface antigen (HBsAg) levels three years before HBsAg seroclearance. Hepatology 2012;56:812-19
50. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352: 2682-95
51. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: A randomised trial. Lancet 2005;365:123-9
52. Chan HL, Hui AY, Wong VW, et al. Long-Term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. Hepatology 2005;41:1357-64
53. Wong GL, Chan HL. Predictors of treatment response in chronic hepatitis B. Drugs 2009;69:2167-77
54. Westland C, Delaney W, Yang H, et al. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil. Gastroenterology 2003;125:107-16
55. Chan HL, Wong ML, Hui AY, et al. Hepatitis B virus genotype has no impact on hepatitis B e antigen seroconversion after lamivudine treatment. World J Gastroenterol 2003;9:2695-7
56. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-63
57. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-31
58. Chan HL, Wong VW, Hui AY, et al. Long-Term lamivudine treatment is associated with a good maintained response in severe acute exacerbation of chronic HBeAg-negative hepatitis B. Antivir Ther 2006;11(4):465-71
59. Wong VW, Wong GL, Tsang SW, et al. Long-Term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B. Antivir Ther 2008;13(4):571-9
60. Lok AS, Lai CL, Leung WY, et al. Long-Term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003;125:1714-22
61. Allen MI, DesLauriers M, Andrews CW, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998;27:1670-7
62. Libbrecht E, Doutreloigne J, Van De Velde H, et al. Evolution of primary and compensatory lamivudine resistance mutations in chronic hepatitis B virus-infected patients during long-Term lamivudine treatment, assessed by a line probe assay. J Clin Microbiol 2007;45(12): 3935-41
63. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348: 808-16
64. Hadziayannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-7
65. Hadziayannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-Term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131:1743-51
66. Hartono JL, Aung MO, Dan YY, et al. Resolution of adefovir-related nephrotoxicity by adefovir dose-reduction in patients with chronic hepatitis B. Aliment Pharmacol Ther 2013;37:710-19
67. Kim du H, Sung DH, Min YK. Hypophosphatemic osteomalacia induced by low-dose adefovir therapy: Focus on manifestations in the skeletal system and literature review. J Bone miner Metab 2013; 31(2):240-6
68. Wedemeyer H, Yurdaydin C, Dalekos GN, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011;364:322-31
69. Chang TT, Gish RG, De Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-10
70. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-20
71. Leung N, Peng CY, Hann HW, et al. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. Hepatology 2009;49:72-9
72. Tenney DJ, Rose RE, Baldick CJ, et al. Long-Term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 2009;49: 1503-14
73. Shaw T, Bartholomeusz A, Locarnini S. HBV drug resistance mechanisms, detection and interpretation. J Hepatol 2006;44: 593-606
74. Reijnders JG, Deterding K, Petersen J, et al. Antiviral effect of entecavir in chronic hepatitis B: Influence of prior exposure to nucleos(t)ide analogues. J Hepatol 2010;52: 493-500
75. Ong A, Wong VW, Wong GL, et al. Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir. Aliment Pharmacol Ther 2011;34:972-81
76. Lange CM, Bojunga J, Hofmann WF, et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009;50:2001-6
77. Wong VW, Wong GL, Yiu KK, et al. Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. J Hepatol 2011;54:236-42
78. Liaw YF, Sheen IS, Lee CM, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011;53:62-72
79. Wong GL, Chan HL, Chan HY, et al. Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment. Gastroenterology 2013;144: 933-44
80. Wong GL, Chan HL, Mak CH, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 2013. [Epub ahead of print]
81. Wong GL. Who will have the best response to entecavir?. J Gastroenterol Hepatol 2013;28:5-7
82. Chang TT, Liaw YF, Wu SS, et al. Long-Term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010;52: 886-93
83. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357:2576-88
84. Chan HL, Heathcote EJ, Marcellin P, et al. Treatment of hepatitis B e antigen-positive chronic hepatitis with telbivudine or adefovir. Ann Intern Med 2007;147:745-54
85. Chan HL, Chen YC, Gane EJ, et al. Randomized clinical trial: Efficacy and safety of telbivudine and lamivudine in treatment-naïve patients with HBV-related decompensated cirrhosis. J Viral Hepat 2012;19:732-43
86. Gane EJ, Deray G, Liaw YF, et al. Telbivudine improves renal function in patients with chronic hepatitis B. Gastroenterology 2014;146(1):138-146.e5
87. Liaw YF, Gane E, Leung N, et al. 2-year GLOBE trial results: Telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009;136: 486-95
88. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil Fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442-55
89. Heathcote EJ, Marcellin P, Buti M, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011;140: 132-43
90. Tan J, Degertekin B, Wong SN, et al. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol 2008;48:391-8
91. van Bömmel F, Trojan J, Deterding K, et al. Evolution of adefovir-resistant HBV polymerase gene variants after switching to tenofovir disoproxil fumarate monotherapy. Antivir Ther 2012;17(6):1049-58
92. Sheldon J, Camino N, Rodes B, et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 2005;10:727-34
93. Amini-Bavil-Olyaee S, Herbers U, Sheldon J, et al. The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains. Hepatology 2009;49:1158-65
94. Cooper RF, Wiebe N, Smith N, et al. Systemic review and meta-Analysis: Renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 2010;51:496-505
95. van Bömmel F, De Man RA, Wedemeyer H, et al. Long-Term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010;51:73-80
96. Gish RG, Clark MD, Kane SD, et al. Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B. Clin Gastroenterol Hepatol 2012;10(8):941-6
97. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: A 5-year open-label follow-up study. Lancet 2013;381:468-75
98. Yoo BC, Kim JH, Chung YH, et al. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 2007;45:1172-8
99. Yoo BC, Kim JH, Kim TH, et al. Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-Therapy viral suppression. Hepatology 2007;46:1041-8
100. Yuen MF, Seto WK, Chow DH, et al. Long-Term lamivudine therapy reduces the risk of long-Term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther 2007;12:1295-303
101. Eun JR, Lee HJ, Lee SH, et al. The effect of lamivudine and adefovir dipivoxil on preventing hepatocellular carcinoma in hepatitis B virus-related liver cirrhosis. Hepatology 2007;46:664A-5A
102. Wong VW, Chan HL. Severe acute exacerbation of chronic hepatitis B: A unique presentation of a common disease. J Gastroenterol Hepatol 2009;24:1179-86
103. Chan HL, Wong VW, Hui AY, et al. Long-Term lamivudine treatment is associated with a good maintained response in severe acute exacerbation of chronic HBeAg-negative hepatitis B. Antivir Ther 2006;11:465-71
104. Wong VW, Wong GL, Yiu KK, et al. Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. J Hepatol 2011;54:236-42
105. Shiffman ML. Management of acute hepatitis B. Clin Liver Dis 2010;14:75-91
106. Loomba R, Rowley AK, Wesley R, et al. Hepatitis B immunoglobulin and lamivudine improve hepatitis B-related outcomes after liver transplantation: Meta-Analysis. Clin Gastroenterol Hepatol 2008;6:696-700
107. Fung J, Cheung C, Chan SC, et al. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology 2011;141: 1212-19
108. Fung J, Chan SC, Cheung C, et al. Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B. Am J Gastroenterol 2013;108:942-8
109. Shouval D, Shibolet O. Immunosuppression and HBV reactivation. Semin Liver Dis 2013;33:167-77
110. Yeo W, Chan HL. Hepatitis B virus reactivation associated with anti-neoplastic therapy. J Gastroenterol Hepatol 2013; 28(1):31-7
111. Gavazzi G, Bouchard O, Leclercq P, et al Change in transaminases in hepatitis C virus-And HIV co-infected patients after highly active antiretroviral therapy: Differences between complete and partial virologic responders?. AIDS Res Hum Retroviruses 2000;16:1021-3
112. Drake A, Mijch A, Sasadeusz J. Immune reconstitution hepatitis in HIV and hepatitis B co-infection despite lamivudine therapy as a part of HAART. Clin Infect Dis 2004;39: 129-32
113. Shi Z, Yang Y, Ma L, et al. Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus, A systematic review and meta-Analysis. Obstet Gynecol 2010;116:147-59
114. Sung JJ, Lai JY, Zeuzem S, et al. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol 2008;48:728-35
115. Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005;129:528-36
116. Lok AS, Trinh H, Carosi G, et al. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B. Gastroenterology 2012;143:619-28
117. Petersen J, Ratziu V, Buti M, et al. Entecavir plus tenofovir combination as rescue therapy in pre-Treated chronic hepatitis B patients: An international multicenter cohort study. J Hepatol 2012;56:520-6
118. Si-Ahmed SN, Pradat P, Zoutendijk R, et al. Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: A European multicenter study. Antiviral Res 2011;92:90-5
119. Chan HL, Hui AJ, Chan S, et al. Tenofovir DF (TDF) compared to emtricitabine (FTC)/TDF in HBeAg-positive, chronic hepatitis B (CHB) virus-infected patients in the immune tolerant (IT) phase. 48th Annual Meeting of the European Association for the Study of the Liver (EASL 2013) (Abstract 101 24-28 April 2013, Amsterdam, Netherlands
120. Chen X, Cao Z, Liu Y, et al. Potent hepatitis B surface antigen response to treatment of hepatitis-B-e-Antigen-positive chronic hepatitis B with a-interferon plus a nucleos(t)ide analog. J Gasteoenterol Hepatol 2012;27(3):481-6
121. Piratvisuth T, Lau GK, Chao YC, et al. Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. Hepatol Int 2008;2:102-10
122. Piccolo P, Lenci I, Demelia L, et al. A randomized controlled trial of pegylated interferon-Alpha2a plus adefovir dipivoxil for hepatitis B e antigen negative chronic hepatitis B. Antivir Ther 2009;14:1165-74
123. Sarin SK, Sood A, Kumar M, et al. Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B. Am J Gastroenterol 2007; 102(1):96-104
124. Moucari R, Boyer N, Ripault MP, et al. Sequential therapy with adefovir dipivoxil and pegylated interferon alfa-2a for HBeAg-negative patients. J Viral Hepat 2011;18:580-6
125. Chen CC, Wang PC, Chang HW, Chen CF. Safety and efficacy of two-step peginterferon a-2a treatment in patients of chronic hepatitis B with acute exacerbation. J Viral Hepat 2012;19:161-92
126. Safadi R, Xie Q, Chen Y, et al. Efficacy of switching to telbivudine in chronic hepatitis B patients treated previously with lamivudine. Liver Int 2011;31(5):667-75
127. Zeuzem S, Gane E, Liaw YF, et al. Baseline characteristics and early on-Treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol 2009;51:11-20
128. Seto WK, Lai CL, Fung J, et al. Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome. J Hepatol 2011;55:522-8
129. Piratvisuth T, Komolmit P, Tanwandee T, et al. 52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B. PLoS One 2013;8(2):e54279
130. Yu HC, Lin KH, Hsu PI, et al. Real-would application of the roadmap model in chronic hepatitis B patients with telbivudine therapy. Clin Ther 2013;35:1386-99
131. Lo AO, Wong VW, Wong GL, et al. Efficacy of entecavir switch therapy in chronic hepatitis B patients with incomplete virological response to telbivudine. Antivir Ther 2013;18(5):671-9
132. Pan CQ, Hu KQ, Yu AS, et al. Response to tenofovir monotherapy in chronic hepatitis B patients with suboptimal response to entecavir. J Viral Hepat 2012;19:213-19
133. Babusis D, Phan TK, Lee WA, et al. Mechanism for Effective Lymphoid Cell and Tissue Loading Following Oral Administration of Nucleotide Prodrug GS-7340. Mol Pharm 2013;10(2):459-66
134. Lai CL, Ahn SH, Lee KS, et al. Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B. Gut 2013. [Epub ahead of print]
135. Grimm D, Thimme R, Blum HE. HBV life cycle and novel drug targets. Hepatol Int 2011;5:644-53
136. Gripon P, Cannie I, Urban S. Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein. J Virol 2005;79(3): 1613-22
137. Petersen J, Dandri M, Mier W, et al. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol 2008;26:335-41
138. Wu HL, Huang LR, Huang CC, et al. RNA interference-mediated control of hepatitis B virus and emergence of resistant mutant. Gastroenterology 2005;128:708-16
139. Asif-Ullah M, Choi KJ, Choi KI, et al. Identification of compounds that inhibit the interaction between core and surface protein of hepatitis B virus. Antiviral Res 2006;70: 85-90
140. Lv S, Wang J, Dou S, et al. Nanoparticles encapsulating hepatitis B virus cytosine-phosphate-guanosine induce therapeutic immunity against HBV infection. Hepatology 2014;59:385-94
141. Kitrinos KM, Corsa A, Liu Y, et al. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology 2014; 59(2):434-42
142. Study to evaluate the efficacy and safety of tenofovir disoproxil fumarate (TDF) in combination with peginterferon a-2a vs standard of care tenofovir disoproxil fumarate monotherapy or peginterferon a-2a monotherapy for 48 weeks in chronic hepatitis B(CHB). (TDF PEG CHB). Clinicaltrials.gov Identifier NCT01277601. Available from: Http://clinicaltrials.gov/show/ NCT01277601
143. An open-label trial of 48-week peginterferon Alfa-2a (PEGASYS) to assess the sustained response of chronic hepatitis B patients with HBeAg seroconversion on nucleot(s)ide analogue therapy. Clinicaltrials.gov Identifier NCT02068365. Available from: Http://clinicaltrials.gov/ct2/show/NCT02068365